LONA (LeonaBio, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by LONA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-10 | JOSEPH EDELMAN | Director | A | — | — |
| 2026-07-09 | JOSEPH EDELMAN | Director | A | — | — |
| 2026-06-24 | Peter B. Silverman | Director | A | — | — |
| 2026-06-24 | Fred Callori | Director | A | — | — |
| 2026-06-24 | Michael A. Panzara | Director | A | — | — |
| 2026-06-24 | JOSEPH EDELMAN | Director | A | — | — |
| 2026-06-24 | Barbara Kosacz | Director | A | — | — |
| 2026-06-24 | Natalie C. Holles | Director | A | — | — |
| 2026-06-24 | GRANT PICKERING | Director | A | — | — |
| 2026-06-24 | Kelly A Romano | Director | A | — | — |
| 2026-06-24 | JAMES A JOHNSON | Director | A | — | — |
| 2026-05-07 | Natalie C. Holles | Director | A | — | — |
| 2026-05-07 | Peter B. Silverman | Director | A | — | — |
| 2026-05-07 | Fred Callori | Director | A | — | — |
| 2026-04-13 | KEVIN CHURCH | CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2026-04-13 | Martin Javier San | CHIEF MEDICAL OFFICER | A | — | — |
| 2026-04-13 | Robert Renninger | CHIEF FINANCIAL OFFICER | A | — | — |
| 2026-04-13 | JOHN M JR FLUKE | Director | A | — | — |
| 2026-04-13 | JAMES A JOHNSON | Director | A | — | — |
| 2026-04-13 | Mark James Litton | PRESIDENT and CEO | A | — | — |
| 2026-04-13 | JOSEPH EDELMAN | Director | A | — | — |
| 2026-04-13 | Kelly A Romano | Director | A | — | — |
| 2026-04-13 | GRANT PICKERING | Director | A | — | — |
| 2026-04-13 | Barbara Kosacz | Director | A | — | — |
| 2026-04-13 | Mark Worthington | GENERAL COUNSEL and CCO | A | — | — |
| 2026-04-13 | Michael A. Panzara | Director | A | — | — |
| 2026-03-05 | KEVIN CHURCH | CHIEF SCIENTIFIC OFFICER | MIXED | — | — |
| 2026-03-05 | Mark Worthington | GENERAL COUNSEL and CCO | MIXED | — | — |
| 2026-03-05 | Robert Renninger | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-03-05 | Martin Javier San | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-03-05 | Mark James Litton | PRESIDENT and CEO | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | PRESIDENT and CEO | 58,582 | — |
| — | CHIEF SCIENTIFIC OFFICER | 25,178 | — |
| — | GENERAL COUNSEL and CCO | 19,704 | — |
| — | CHIEF MEDICAL OFFICER | 17,607 | — |
| — | CHIEF FINANCIAL OFFICER | 16,757 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LONA quote page; the site-wide leaderboard is on the insider transactions hub.